[1] |
LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
|
[2] |
DOHERTY DG. Antigen-specific immune tolerance in the liver[J]. Nat Biomed Eng, 2019, 3(10): 763-765. DOI: 10.1038/s41551-019-0445-9.
|
[3] |
GRANT CR, LIBERAL R. Liver immunology: How to reconcile tolerance with autoimmunity[J]. Clin Res Hepatol Gastroenterol, 2017, 41(1): 6-16. DOI: 10.1016/j.clinre.2016.06.003.
|
[4] |
TANAKA A, LEUNG P, GERSHWIN ME. The genetics of primary biliary cholangitis[J]. Curr Opin Gastroenterol, 2019, 35(2): 93-98. DOI: 10.1097/MOG.0000000000000507.
|
[5] |
TSUNEYAMA K, BABA H, MORIMOTO Y, et al. Primary biliary cholangitis: Its pathological characteristics and immunopathological mechanisms[J]. J Med Invest, 2017, 64(1.2): 7-13. DOI: 10.2152/jmi.64.7.
|
[6] |
LLEO A, LEUNG P, HIRSCHFIELD GM, et al. The pathogenesis of primary biliary cholangitis: A comprehensive review[J]. Semin Liver Dis, 2020, 40(1): 34-48. DOI: 10.1055/s-0039-1697617.
|
[7] |
ARSENIJEVIC A, STOJANOVIC B, MILOVANOVIC J, et al. Galectin-3 in inflammasome activation and primary biliary cholangitis development[J]. Int J Mol Sci, 2020, 21(14). DOI: 10.3390/ijms21145097.
|
[8] |
RONCA V, MANCUSO C, MILANI C, et al. Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis[J]. J Leukoc Biol, 2020, 108(2): 659-671. DOI: 10.1002/JLB.5MR0320-200R.
|
[9] |
GIORDANO DM, PINTO C, MARONI L, et al. Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies[J]. Int J Mol Sci, 2018, 19(10): 3003. DOI: 10.3390/ijms19103003.
|
[10] |
TANAKA A, LEUNG P, GERSHWIN ME. Evolution of our understanding of PBC[J]. Best Pract Res Clin Gastroenterol, 2018, 34-35: 3-9. DOI: 10.1016/j.bpg.2018.05.008.
|
[11] |
TAYLOR SA, ASSIS DN, MACK CL. The contribution of B cells in autoimmune liver diseases[J]. Semin Liver Dis, 2019, 39(4): 422-431. DOI: 10.1055/s-0039-1688751.
|
[12] |
CHUNG BK, GUEVEL BT, REYNOLDS GM, et al. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis[J]. J Autoimmun, 2017, 77: 45-54. DOI: 10.1016/j.jaut.2016.10.003.
|
[13] |
MA WT, CHEN DK. Immunological abnormalities in patients with primary biliary cholangitis[J]. Clin Sci (Lond), 2019, 133(6): 741-760. DOI: 10.1042/CS20181123.
|
[14] |
FU HY, BAO WM, YANG CX, et al. Kupffer cells regulate natural killer cells via the NK group 2, member D (NKG2D)/retinoic acid early inducible-1 (RAE-1) interaction and cytokines in a primary biliary cholangitis mouse model[J]. Med Sci Monit, 2020, 26: e923726. DOI: 10.12659/MSM.923726.
|
[15] |
HYDES TJ, BLUNT MD, NAFTEL J, et al. Constitutive activation of natural killer cells in primary biliary cholangitis[J]. Front Immunol, 2019, 10: 2633. DOI: 10.3389/fimmu.2019.02633.
|
[16] |
LI Y, LI B, YOU Z, et al. Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis[J]. J Autoimmun, 2019, 103: 102293. DOI: 10.1016/j.jaut.2019.06.004.
|
[17] |
BERNTSEN NL, FOSBY B, TAN C, et al. Natural killer T cells mediate inflammation in the bile ducts[J]. Mucosal Immunol, 2018, 11(6): 1582-1590. DOI: 10.1038/s41385-018-0066-8.
|
[18] |
ZHAO SX, LI WC, FU N, et al. Emperipolesis mediated by CD8(+) T cells correlates with biliary epithelia cell injury in primary biliary cholangitis[J]. J Cell Mol Med, 2020, 24(2): 1268-1275. DOI: 10.1111/jcmm.14752.
|
[19] |
CHEN Q, LAI L, CHI X, et al. CD19(+)CD24(hi)CD38(hi) B cell dysfunction in primary biliary cholangitis[J]. Mediators Inflamm, 2020, 2020: 3019378. DOI: 10.1155/2020/3019378.
|
[20] |
GREEN DS, YOUNG HA, VALENCIA JC. Current prospects of type Ⅱ interferon γ signaling and autoimmunity[J]. J Biol Chem, 2017, 292(34): 13925-13933. DOI: 10.1074/jbc.R116.774745.
|
[21] |
YANG C, MAI H, PENG J, et al. STAT4: An immunoregulator contributing to diverse human diseases[J]. Int J Biol Sci, 2020, 16(9): 1575-1585. DOI: 10.7150/ijbs.41852.
|
[22] |
TANAKA A, LEUNG P, YOUNG HA, et al. Therapeutic and immunological interventions in primary biliary cholangitis: From mouse models to humans[J]. Arch Med Sci, 2018, 14(4): 930-940. DOI: 10.5114/aoms.2017.70995.
|
[23] |
CAPONE A, VOLPE E. Transcriptional regulators of T helper 17 cell differentiation in health and autoimmune diseases[J]. Front Immunol, 2020, 11: 348. DOI: 10.3389/fimmu.2020.00348.
|
[24] |
DRESCHER HK, BARTSCH LM, WEISKIRCHEN S, et al. Intrahepatic TH17/TReg cells in homeostasis and disease-it's all about the balance[J]. Front Pharmacol, 2020, 11: 588436. DOI: 10.3389/fphar.2020.588436.
|
[25] |
SUN Q, WANG Q, FENG N, et al. The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis[J]. Ann Transl Med, 2019, 7(16): 389. DOI: 10.21037/atm.2019.07.100.
|
[26] |
CHEN J, HOU X, JIA H, et al. Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis[J]. Oncotarget, 2017, 8(65): 108406-108417. DOI: 10.18632/oncotarget.22658.
|
[27] |
LIASKOU E, PATEL SR, WEBB G, et al. Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells[J]. J Autoimmun, 2018, 94: 143-155. DOI: 10.1016/j.jaut.2018.07.020.
|
[28] |
ZHANG Q, LU W, LIANG CL, et al. Chimeric antigen receptor (CAR) Treg: A promising approach to inducing immunological tolerance[J]. Front Immunol, 2018, 9: 2359. DOI: 10.3389/fimmu.2018.02359.
|